Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
23.04. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the LSX World Congress 2024 | 251 | ACCESSWIRE | Presentation on Monday, April 29th at 4:15 PM (GMT+1)HOUSTON, TX / ACCESSWIRE / April 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing... ► Artikel lesen | |
22.04. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity | 258 | ACCESSWIRE | Live video webcast with Chief Executive Officer, John Climaco, on Tuesday, April 23rd at 12:00 PM ETHOUSTON, TX / ACCESSWIRE / April 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the... ► Artikel lesen | |
13.04. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
01.04. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements | 266 | ACCESSWIRE | Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM studyBerubicin study... ► Artikel lesen | |
01.04. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
01.04. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at Two Investor Conferences in April | 307 | ACCESSWIRE | HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
21.02. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
02.02. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
30.01. | CNS Pharmaceuticals prices $4M public offering | 5 | Seeking Alpha | ||
30.01. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering | 634 | ACCESSWIRE | HOUSTON, TX / ACCESSWIRE / January 29, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
23.01. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
22.01. | CNS Pharmaceuticals, Inc. - S-1/A, General form for registration of securities | 4 | SEC Filings | ||
18.01. | CNS Pharmaceuticals, Inc.: Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors | 456 | ACCESSWIRE | Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and immunologyHOUSTON... ► Artikel lesen | |
17.01. | CNS Pharmaceuticals completes enrollment for brain cancer study | 3 | Investing.com | ||
17.01. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme | 266 | ACCESSWIRE | HOUSTON, TX / ACCESSWIRE / January 17, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
10.01. | CNS Pharmaceuticals, Inc. - S-1/A, General form for registration of securities | 5 | SEC Filings | ||
18.12.23 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin | 301 | ACCESSWIRE | Independent DSMB recommends continuing clinical trial of Berubicin without modificationEnrollment expected to be complete in early Q1 2024HOUSTON, TX / ACCESSWIRE / December 18, 2023 / CNS Pharmaceuticals... ► Artikel lesen | |
18.12.23 | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
08.12.23 | CNS Pharmaceuticals files to sell 3.81M shares of common stock | 6 | Seeking Alpha | ||
08.12.23 | CNS Pharmaceuticals, Inc. - S-1, General form for registration of securities | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CUREVAC | 2,586 | +9,11 % | CureVac: Nächste Woche könnte es brenzlig werden! | Verzweiflung machte sich zuletzt breit bei CureVac-Aktionären. So gab der Kurs im Verhältnis zur Vorwoche 6,29 Prozent nach. Mit Rücksetzern beendete das Wertpapier insgesamt zwei der fünf Handelstage.... ► Artikel lesen | |
CORE ONE LABS | 0,137 | -9,27 % | Sondermeldung: Gar mehrere hundert Prozent bis zur Bescherung? Wo die Community jetzt auf eine Jahresendrallye spekuliert… | ||
QIAGEN | 39,585 | +1,29 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
EVOTEC | 9,895 | +1,59 % | Evotec nach dem Horror-Crash - war's das? | Die Kursentwicklung des einstigen deutschen Biotech-Vorzeige-Unternehmens Evotec in den vergangenen Monaten gleicht einem Trauerspiel. Notierte die Aktie vor knapp einem Jahr noch über 24 Euro, so ist... ► Artikel lesen | |
VERA THERAPEUTICS | 43,500 | +2,81 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
MORPHOSYS | 66,10 | -0,15 % | Flut an Quartalszahlen: So reagiert der DAX - Außerdem im Fokus: Adidas und MorphoSys | Am Dienstag sind eine ganze Fülle von wichtigen Quartalszahlen präsentiert worden. Wie reagiert der deutsche Leitindex darauf? Außerdem im Fokus: Adidas und MorphoSys. Die Anleger am deutschen Aktienmarkt... ► Artikel lesen | |
JANUX THERAPEUTICS | 62,43 | +7,29 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
SPRINGWORKS THERAPEUTICS | 43,320 | -7,51 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
APOGEE THERAPEUTICS | 52,20 | +2,55 % | Apogee Therapeutics, Inc.: Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases | Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 19,290 | +1,47 % | Edgewise Therapeutics: Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies | Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designations for sevasemten... ► Artikel lesen | |
CYTOMX THERAPEUTICS | 4,190 | +173,50 % | CytomX-Aktie +259%: Top-Empfehlung dreht völlig durch! | Mit der Aktie des Biotech-Unternehmens CytomX Therapeutics (WKN: A14158) knallt einer unserer Top-Tipps am Mittwoch in der Spitze um +259% von 1,63 US$ bis auf 5,85 US$ in die Höhe - bei absoluten Rekordumsätzen... ► Artikel lesen | |
BIONTECH | 85,65 | +2,39 % | BioNTech: Bringen Sie sich in Sicherheit! | Zahlreiche Nackenschläge müssen heute die Anteilseigner von BioNTech hinnehmen. Denn die Aktie stürzt mit einem Minus von rund zwei Prozent regelrecht ab. Ein Anteilsschein ist damit nur 80,85 EUR wert.... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 25,580 | -0,85 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,790 | +5,40 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
C4 THERAPEUTICS | 6,430 | -1,68 % | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen |